2023
Perioperative Immunosuppression in Inflammatory Bowel Disease
Leeds I, Lightner A, Kurowski J. Perioperative Immunosuppression in Inflammatory Bowel Disease. 2023, 613-617. DOI: 10.1007/978-3-031-14744-9_43.ChaptersInflammatory bowel diseaseBowel diseasePotential postoperative morbidityChronic steroid useEndoscopic remissionPostoperative morbidityPerioperative effectsPerioperative periodPharmacologic therapyPostoperative outcomesPerioperative immunosuppressionUlcerative colitisCrohn's diseaseImmunosuppressive agentsOpportunistic infectionsSteroid useImmunosuppressive effectsImmunosuppressive propertiesMonoclonal antibodiesDiseaseImmunosuppressionHigh rateRiskColitisCorticosteroidsWolff-Parkinson-White (WPW) Syndrome
Vinocur J. Wolff-Parkinson-White (WPW) Syndrome. In Clinical Practice 2023, 103-127. DOI: 10.1007/978-3-031-41479-4_6.Peer-Reviewed Original ResearchAsymptomatic patientsRisk stratificationSudden deathCalcium channel blockersEarliest atrial activationAntidromic AVRTAsymptomatic WPWOrthodromic AVRTPharmacologic therapyUncommon manifestationCatheter ablationVariety of manifestationsAtrial fibrillationPathway conductionWolff-ParkinsonAccessory pathwaySerious manifestationsVentricular pacingBidirectional accessory pathwaysCatheter stabilityWhite syndromeAtrial activationFirst lesionPatientsWPW
2021
Hepatocyte-specific suppression of ANGPTL4 improves obesity-associated diabetes and mitigates atherosclerosis in mice
Singh AK, Chaube B, Zhang X, Sun J, Citrin KM, Canfrán-Duque A, Aryal B, Rotllan N, Varela L, Lee RG, Horvath TL, Price N, Suárez Y, Fernandez-Hernando C. Hepatocyte-specific suppression of ANGPTL4 improves obesity-associated diabetes and mitigates atherosclerosis in mice. Journal Of Clinical Investigation 2021, 131 PMID: 34255741, PMCID: PMC8409581, DOI: 10.1172/jci140989.Peer-Reviewed Original ResearchDiet-induced obesityGlucose intoleranceHigh-fat fed conditionsLipoprotein lipaseExcess hepatic lipid accumulationSystemic metabolic dysfunctionRole of ANGPTL4Liver lipid metabolismHepatic lipid accumulationTargeted pharmacologic therapyANGPTL4 gene expressionMetabolic turnover studiesHepatic lipase activityObesity-associated diabetesFatty acidsNovel inhibition strategiesPharmacologic therapyLiver steatosisLiver damageLipoprotein remnantsCholesterol levelsMetabolic dysfunctionHepatic uptakeANGPTL4 deficiencyHL activityVTE Prophylaxis in Critically Ill Adults A Systematic Review and Network Meta-analysis
Fernando SM, Tran A, Cheng W, Sadeghirad B, Arabi YM, Cook DJ, Møller MH, Mehta S, Fowler RA, Burns KEA, Wells PS, Carrier M, Crowther MA, Scales DC, English SW, Kyeremanteng K, Kanji S, Kho ME, Rochwerg B. VTE Prophylaxis in Critically Ill Adults A Systematic Review and Network Meta-analysis. CHEST Journal 2021, 161: 418-428. PMID: 34419428, DOI: 10.1016/j.chest.2021.08.050.Peer-Reviewed Original ResearchConceptsIncidence of DVTRandomized clinical trialsMechanical compressive deviceRisk of DVTIll adultsCombination therapyRCTs of patientsSystematic reviewAdults A Systematic ReviewCombination pharmacologic therapyCompressive devicePrimary pharmacologic agentsRisk of VTELow-certainty evidencePrevention of VTEA Systematic ReviewNetwork Meta-AnalysisFull-text reviewThromboprophylaxis agentsVenous thromboprophylaxisVTE prophylaxisRecommendations AssessmentPharmacologic therapyPulmonary embolismIll patientsBehavioral Variant Frontotemporal Dementia: Diagnosis and Treatment Interventions
Balachandran S, Matlock E, Conroy M, Lane C. Behavioral Variant Frontotemporal Dementia: Diagnosis and Treatment Interventions. Current Geriatrics Reports 2021, 10: 101-107. DOI: 10.1007/s13670-021-00360-y.Peer-Reviewed Original ResearchVariant frontotemporal dementiaFrontotemporal dementiaCommon dementia syndromesCornerstone of treatmentNon-pharmacologic interventionsNon-pharmacologic managementCurrent pharmacologic therapiesBehavioral variant frontotemporal dementiaPrimary psychiatric illnessProgressive neurodegenerative disorderClinical research stagePharmacologic therapyDiagnostic workupDementia syndromesPsychiatric illnessTreatment interventionsCaregiver supportCholinesterase inhibitorsCertain symptomsReviewThe diagnosisBrain circuitsNeurodegenerative disordersEmotional bluntingDementiaBehavioral disinhibitionTubular Cell Dropout in Preimplantation Deceased Donor Biopsies as a Predictor of Delayed Graft Function
Avigan ZM, Singh N, Kliegel JA, Weiss M, Moeckel GW, Cantley LG. Tubular Cell Dropout in Preimplantation Deceased Donor Biopsies as a Predictor of Delayed Graft Function. Transplantation Direct 2021, 7: e716. PMID: 34476295, PMCID: PMC8384397, DOI: 10.1097/txd.0000000000001168.Peer-Reviewed Original ResearchDeceased donor kidney transplantDonor biopsiesGraft functionTubular injuryTubular cellsDelayed graft functionAcute tubular injuryDonor kidney transplantsConventional histopathologic evaluationPotential therapeutic interventionsMass cytometry analysisTubular cell lossDGF riskGraft outcomeTransplant recipientsKidney transplantPharmacologic therapyDeceased donorsMacrophage infiltrationHistopathologic evaluationLiving donorsDonor factorsCold ischemiaHistopathologic analysisCell dropoutRisk reduction and pharmacological strategies to prevent progression of aortic aneurysms
Weininger G, Chan SM, Zafar M, Ziganshin BA, Elefteriades JA. Risk reduction and pharmacological strategies to prevent progression of aortic aneurysms. Expert Review Of Cardiovascular Therapy 2021, 19: 619-631. PMID: 34102944, DOI: 10.1080/14779072.2021.1940958.Peer-Reviewed Original ResearchConceptsAortic aneurysmAbdominal aortic aneurysmß-blockersAngiotensin II receptor blockersAngiotensin-converting enzyme inhibitorAnti-platelet medicationDifferent pharmacologic therapiesII receptor blockersAortic aneurysm patientsThoracic aortic aneurysmRisk reductionAortic aneurysm growthPharmacologic managementReceptor blockersPharmacologic therapyMedical therapySurgical interventionAneurysm patientsMiscellaneous drugsAneurysm diseasePharmacological strategiesSyndrome patientsMarfan syndromeEnzyme inhibitorsAneurysms
2019
A systematic review and network meta-analysis of existing pharmacologic therapies in patients with idiopathic sudden sensorineural hearing loss
Ahmadzai N, Kilty S, Cheng W, Esmaeilisaraji L, Wolfe D, Bonaparte JP, Schramm D, Fitzpatrick E, Lin V, Skidmore B, Moher D, Hutton B. A systematic review and network meta-analysis of existing pharmacologic therapies in patients with idiopathic sudden sensorineural hearing loss. PLOS ONE 2019, 14: e0221713. PMID: 31498809, PMCID: PMC6733451, DOI: 10.1371/journal.pone.0221713.Peer-Reviewed Original ResearchConceptsIdiopathic sudden sensorineural hearing lossSudden sensorineural hearing lossSensorineural hearing lossPTA improvementSystemic steroidsHearing recoveryHearing lossHigh riskManagement of ISSNHLSystematic reviewPure-tone average improvementSystemic steroid treatmentCause of disabilityExperienced information specialistSelection of treatmentQuality of lifeMajority of casesRemoval of duplicatesIntratympanic steroidsIntravenous steroidsIT steroidsOral steroidsPharmacologic therapySteroid treatmentActive treatmentSurgical Treatment of Chronic Hand Ischemia: A Systematic Review and Case Series
Colen DL, Ben-Amotz O, Stephanie T, Serebrakian A, Carney MJ, Gerety PA, Levin LS. Surgical Treatment of Chronic Hand Ischemia: A Systematic Review and Case Series. The Journal Of Hand Surgery (Asian-Pacific Volume) 2019, 24: 359-370. PMID: 31438795, DOI: 10.1142/s2424835519500462.Peer-Reviewed Original ResearchConceptsChronic hand ischemiaHand ischemiaNew ulcerationSurgical interventionSurgical treatmentSystematic reviewLast-line treatmentRest painArtery bypassIschemic symptomsMedical optimizationConservative treatmentPharmacologic therapyPrimary outcomeSecondary amputationVenous arterializationCase seriesLine treatmentCold intoleranceMore complicationsArterial bypassConservative measuresSurgical techniqueIschemiaPRISMA guidelinesUsing nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support
Muthulingam D, Bia J, Madden LM, Farnum SO, Barry DT, Altice FL. Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support. Journal Of Substance Use And Addiction Treatment 2019, 100: 18-28. PMID: 30898324, PMCID: PMC6432946, DOI: 10.1016/j.jsat.2019.01.019.Peer-Reviewed Original ResearchConceptsOpioid use disorderNominal group techniquePharmacologic therapyUse disordersSyringe exchange programsIndividual-level barriersEvidence-based interventionsAddiction treatment centersEvidence-based strategiesOUD treatmentPharmacologic treatmentSpecific medicationsTreatment optionsPharmacologic propertiesMedicationsDecision aidPatient considerationsSide effectsTreatment centersOpioid crisisSpecific knowledge gapsGroup techniqueDecision aid developmentTreatmentTherapy
2018
The Renal Effects of Aggressive Volume Removal in Heart Failure Patients with Preexisting Worsening Renal Function
Mahoney D, Ahmad T, Rao V, Brisco-Bacik M, Wilson F, Siew E, Felker G, Anstrom K, Bart B, Tang W, O'Connor C, Velazquez E, Testani J. The Renal Effects of Aggressive Volume Removal in Heart Failure Patients with Preexisting Worsening Renal Function. Journal Of Cardiac Failure 2018, 24: s26. DOI: 10.1016/j.cardfail.2018.07.074.Peer-Reviewed Original ResearchRenal tubular injury biomarkersTubular injury biomarkersRenal tubular injuryHeart failure patientsInjury biomarkersTubular injuryFailure patientsRenal functionAcute decompensated heart failure patientsDecompensated heart failure patientsVolume removalCARRESS-HF trialRenal function recoveryTubular injury markersWorsening Renal FunctionHalf of patientsADHF patientsEffective decongestionRenal effectsInjury markersPharmacologic therapyTransient findingFunction recoveryHigh incidencePatientsHemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians.
Qaseem A, Wilt T, Kansagara D, Horwitch C, Barry M, Forciea M, Fitterman N, Balzer K, Boyd C, Humphrey L, Iorio A, Lin J, Maroto M, McLean R, Mustafa R, Tufte J. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Annals Of Internal Medicine 2018, 168: 569-576. PMID: 29507945, DOI: 10.7326/m17-0939.Peer-Reviewed Original ResearchConceptsType 2 diabetesAmerican CollegePharmacologic therapyGlycemic controlGeneral healthScottish Intercollegiate Guidelines NetworkGuidelines International Network libraryClinical Systems ImprovementHemoglobin A1c targetPatient's general healthAmerican Diabetes AssociationAGREE II instrumentLife expectancyNational Guideline ClearinghouseCost of careA1C targetsNonpregnant adultsMost patientsPharmacologic treatmentClinical EndocrinologistsTreatment burdenDiabetes AssociationPatient preferencesChronic conditionsAdvanced age
2017
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians.
Qaseem A, Forciea M, McLean R, Denberg T, Barry M, Cooke M, Fitterman N, Harris R, Humphrey L, Kansagara D, McLean R, Mir T, Schünemann H. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Annals Of Internal Medicine 2017, 166: 818-839. PMID: 28492856, DOI: 10.7326/m15-1361.Peer-Reviewed Original ResearchConceptsLow bone densityBone densityPharmacologic treatmentVertebral fracturesPatient populationAmerican CollegeSystematic reviewACP Clinical Guidelines CommitteeClinical Practice Guideline UpdateLong-term pharmacologic treatmentBone density monitoringClinical Guidelines CommitteeFracture risk profileWomen 65 yearsMenopausal estrogen therapyCost of medicationsLarge observational studiesTreatment of osteoporosisTarget patient populationProgestogen therapyEstrogen therapyAdverse eventsPharmacologic therapyOsteoporotic womenPhysician recommendationSystemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline.
Chou R, Deyo R, Friedly J, Skelly A, Weimer M, Fu R, Dana T, Kraegel P, Griffin J, Grusing S. Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline. Annals Of Internal Medicine 2017, 166: 480-492. PMID: 28192790, DOI: 10.7326/m16-2458.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic low back painAcute low back painLow back painSystemic pharmacologic therapyBack painPain reliefPharmacologic therapySystemic medicationsAmerican CollegeSystematic reviewPhysicians Clinical Practice GuidelineRadicular low back painShort-term pain reliefNonsteroidal anti-inflammatory drugsSecond verified accuracyCochrane Central RegisterClinical practice guidelinesAnti-inflammatory drugsSkeletal muscle relaxantsShort-term trialsEnglish-language studiesModest effectSystemic corticosteroidsAntiseizure medicationsCentral RegisterOral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians.
Qaseem A, Barry M, Humphrey L, Forciea M, Fitterman N, Horwitch C, Kansagara D, McLean R, Wilt T. Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians. Annals Of Internal Medicine 2017, 166: 279-290. PMID: 28055075, DOI: 10.7326/m16-1860.Peer-Reviewed Original ResearchConceptsType 2 diabetesOral pharmacologic treatmentGlycemic controlPharmacologic treatmentPatient populationAmerican CollegeSodium-glucose cotransporter 2 inhibitorsType 2Clinical Practice Guideline UpdateDipeptidyl peptidase-4 inhibitorsCotransporter 2 inhibitorsSGLT-2 inhibitorsSystolic blood pressurePeptidase-4 inhibitorsDPP-4 inhibitorsTarget patient populationTotality of evidenceACP guidelinesCerebrovascular morbidityCause mortalityOral medicationsOral therapyPharmacologic therapyBlood pressureHemoglobin A1cBattlefield Acupuncture
Federman DG, Gunderson CG. Battlefield Acupuncture. Southern Medical Journal 2017, 110: 55-57. PMID: 28052177, DOI: 10.14423/smj.0000000000000584.Peer-Reviewed Original Research
2016
Fracture Prediction With Modified-FRAX in Older HIV-Infected and Uninfected Men
Yin MT, Shiau S, Rimland D, Gibert CL, Bedimo RJ, Rodriguez-Barradas MC, Harwood K, Aschheim J, Justice AC, Womack JA. Fracture Prediction With Modified-FRAX in Older HIV-Infected and Uninfected Men. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2016, 72: 513-520. PMID: 27003493, PMCID: PMC4942335, DOI: 10.1097/qai.0000000000000998.Peer-Reviewed Original ResearchConceptsUninfected menOlder HIVSecondary osteoporosisFRAX calculationVeterans Aging Cohort Study Virtual CohortFracture Risk CalculatorIncident fragility fracturesMajor osteoporotic fractureIncident fracturesPharmacologic therapyFragility fracturesHip fractureHIV statusFracture preventionOsteoporotic fracturesRisk calculatorFracture ratesBone densityCase findingFRAXHIVVirtual cohortOsteoporosisComplete dataMenPharmacologic Therapies in Gastrointestinal Diseases
Fox RK, Muniraj T. Pharmacologic Therapies in Gastrointestinal Diseases. 2016, 100: 827-850. PMID: 27235617, DOI: 10.1016/j.mcna.2016.03.009.Peer-Reviewed Original ResearchMeSH KeywordsAntacidsAnti-Bacterial AgentsAntidepressive AgentsAntidiarrhealsAntiviral AgentsCoinfectionDietary FiberDrug Resistance, ViralGastroesophageal RefluxGastrointestinal AgentsGastrointestinal DiseasesGenotypeHelicobacter InfectionsHepatitis CHistamine H2 AntagonistsHIV InfectionsHumansIrritable Bowel SyndromeLaxativesPeptic UlcerProbioticsProton Pump InhibitorsConceptsGastroesophageal reflux diseaseIrritable bowel syndromeProton pump inhibitorsHepatitis C virusBowel syndromeFirst-line treatmentMainstay of therapyPeptic ulcer diseaseLong-term useHCV treatmentReflux diseaseMost patientsPharmacologic therapyDuodenal ulcerUlcer diseasePump inhibitorsC virusGastrointestinal diseasesTreatment candidatesPermanent cureSevere symptomsSide effectsDiseaseHigher likelihoodPharmacotherapy
2014
Wolff-Parkinson-White (WPW) Syndrome
Vinocur J. Wolff-Parkinson-White (WPW) Syndrome. In Clinical Practice 2014, 55-77. DOI: 10.1007/978-1-4471-5433-4_4.ChaptersAsymptomatic patientsRisk stratificationSudden deathCalcium channel blockersEarliest atrial activationTip Radiofrequency AblationAntidromic AVRTAsymptomatic WPWOrthodromic AVRTPharmacologic therapyUncommon manifestationAtrial pacingCatheter ablationVariety of manifestationsAtrial fibrillationPathway conductionSinus rhythmWolff-ParkinsonAccessory pathwaySerious manifestationsVentricular pacingRadiofrequency ablationBidirectional accessory pathwaysCatheter stabilityWhite syndromePharmacologic Therapy for Pulmonary Arterial Hypertension in Adults CHEST Guideline and Expert Panel Report
Taichman DB, Ornelas J, Chung L, Klinger JR, Lewis S, Mandel J, Palevsky HI, Rich S, Sood N, Rosenzweig EB, Trow TK, Yung R, Elliott CG, Badesch DB. Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults CHEST Guideline and Expert Panel Report. CHEST Journal 2014, 146: 449-475. PMID: 24937180, PMCID: PMC4137591, DOI: 10.1378/chest.14-0793.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionHigh-level evidenceConsensus statementPharmacologic therapyAvailable evidenceArterial hypertensionGrades of RecommendationCochrane Library databasesExpert Panel ReportClinician adviceOptimal pharmacotherapyAdult patientsCHEST GuidelineGuideline recommendationsHigh-level recommendationsClinical questionsLibrary databasesSystematic reviewClinical decisionPharmacotherapyTherapyHypertensionEnglish-language evidenceLevel evidenceFurther studies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply